Minneapolis medical device giant Medtronic (NYSE:MDT) launched a new global study of its Specify 5-6-5 spinal cord stimulation therapy in treatment of patients with failed back surgery syndrome and predominant low back pain.
The PROMISE study, which will enroll up to 300 patients, will evaluate treatment with Specify SCS and drug therapy and compare it to treatment with drug therapy alone.
SPR Therapeutics touted a regulatory win across the pond for its Smartpatch peripheral nerve stimulation system for treating chronic shoulder pain as a result of stroke.
Cleveland, Ohio.-based SPR’s Smartpatch system is a "skin-mounted external stimulator" that can deliver up to 30-days of pain relief, according to a press release.
Cleveland-area startup SPR Therapeutics closed a $7.8 million Series A financing round to commercialize its neurostimulation pain relief device.
The funding came from NDI Healthcare Fund, Public Square Partners and individual investors, according to a press release.
Pain pump maker I-Flow lost a bid for summary judgment in a patient injury lawsuit associated with its On-Q Painbuster continuous infusion drug pump.
The Precision Spectra was cleared for treatment of patients suffering from chronic pain, and the 1st commercial implant of the device was performed in the U.K. last month, according to a press release.